First Tracks Biotherapeutics
TRAX
150 hedge funds and large institutions have $655M invested in First Tracks Biotherapeutics in 2026 Q2 according to their latest regulatory filings, with 150 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
93.36% more ownership
Funds ownership: 0% → 93.36% (+93%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $8K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$59.3M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$54.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$38.4M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
+$38M |
| 5 |
BlackRock
New York
|
+$36.7M |
Top Sellers
TRAX Hedge Fund Activity: Q2 2026 in Review
150 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in First Tracks Biotherapeutics (TRAX) for Q2 2026, worth a combined $655M.
Buyers outnumbered sellers: 150 funds opened new TRAX positions and 0 closed out — a net gain of 150 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $59.3M.
- 150 institutional investors held First Tracks Biotherapeutics (TRAX) as of Q2 2026, up from 0 in Q1 2026.
- Funds reported $655M of First Tracks Biotherapeutics stock for Q2 2026.
- 150 funds opened new First Tracks Biotherapeutics positions in Q2 2026 and 0 closed out, a net change of +150 holders.
- The largest First Tracks Biotherapeutics buyer in Q2 2026 was EcoR1 Capital, an estimated $59.3M added.
Based on aggregated 13F filings for Q2 2026.